APT (adjuvant paclitaxel-trastuzumab)
For small HER2-positive tumours, a gentle regimen of weekly paclitaxel plus trastuzumab gives excellent cure rates, avoiding harsher chemotherapy.
Single-arm: 7-year DFS 93%, 10-year recurrence-free interval 96.3%. Became the standard for stage I disease without a randomised trial. ATEMPT (T-DM1 alone) showed similar efficacy but no toxicity advantage.
- 93 out of 100 people alive without the cancer coming back at 7 years with Paclitaxel + trastuzumab.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Small (≤3 cm), node-negative HER2+ breast cancer: 12 weeks paclitaxel + 1 year trastuzumab. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (HER2); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
410 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| 7-year disease-free survivalprimary | Paclitaxel + trastuzumab | 406 | 93% | — | — | link |
Pages like this
not linked directly; found by shared links- TrialPERSEPHONE
Shares Trastuzumab, Wrong doses, HER2-positive breast cancer.
- TrialHER2CLIMB-05
Shares Trastuzumab, HER2-positive breast cancer.
- IdeaPooled international procurement of essential adult cancer medicines
Shares Paclitaxel / nab-paclitaxel, Trastuzumab.
- TrialDESTINY-Breast09
- IdeaA risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy
Shares Trastuzumab, HER2-positive breast cancer.
- IdeaBiomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy
Shares Trastuzumab, HER2-positive breast cancer.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Trastuzumab, HER2-positive breast cancer.
- PairingTucatinib + trastuzumab + capecitabine for brain metastases
Shares Trastuzumab, HER2-positive breast cancer.